A former adversary of the DEA and HHS now shapes federal drug reform as Deputy General Counsel, steering executive orders and clinical access.

The FDA outlines its ibogaine trial vision, Compass Pathways reveals pricing and slow rollout plans, and early healthcare leaders weigh in—here’s what DMV readers need to know.

The FDA opened a 45‑day comment window on how to safely study ibogaine, seeking input on dosing, cardiac monitoring, ethics, and trial design—without touching legalization debates.

In a unanimous move, Portland will make personal, non-commercial use and sharing of natural psychedelics a low police priority—without legalizing sales or impaired driving.

A DEA administrative judge granted opponents’ request to pause the federal marijuana rescheduling hearing so a GAO report on scheduling “gaps” can be entered. Here’s what that means in practice for DC, Maryland and Virginia.

As microdosing goes mainstream, here’s how to decide between a solo approach or working with a coach—plus DMV-specific considerations and compliance tips.

A practical, ethical guide to talking with parents about psilocybin—what to say, how to support them, and what DC, Maryland, and Virginia residents should know.

Psychedelic Alpha flagged a busy “Psychedelics Week” in DC with multiple meetings. Here’s what that activity could signal for policy, access, and the DMV community.

Pierce County, Nevada City and Portland advance measures to make personal use of natural psychedelics a low police priority—without legalizing them—signaling a local-first policy trend.

State health officials pulled back proposed fee increases for Oregon’s supervised psilocybin program after broad backlash, but funding questions and possible tax changes remain.

Exploring how shared mushroom experiences foster deep human connection amidst evolving drug policy across the DMV region.

Estrogen’s influence on serotonin and glutamate links women’s health to psychedelic care. Here’s what patients and DMV providers should understand now.

Psychedelic Alpha has introduced The Psychedelic News Feed Podcast, creating a new way to follow psychedelics developments. Here’s why DMV readers should care.

As 5‑MeO‑DMT draws buzz, scientists and conservationists warn against “toad milking.” Here’s what’s known, what’s not, and how DMV readers should approach it.

What a new psilocybin trial update means for evidence standards in medical cannabis and patient care, plus why rigorous methods matter for DMV patients.

A small Johns Hopkins pilot gave two psilocybin doses to 20 adults with chronic Lyme symptoms. Participants reported improved sleep and quality of life, and a 40% symptom drop at six months.

A plain‑English guide to where psychedelic-assisted therapy is actually available now, how Oregon, Colorado and New Mexico differ, and what DC, Maryland and Virginia residents should know before making plans.

From West Virginia to Hawaii, lawmakers are prepping for FDA-approved psilocybin drugs—not legalizing mushrooms. Here’s what’s moving, who’s behind it, and how it could affect DMV residents.

Splashy headlines about psilocybin and LSD often outpace the science. Here’s how to read studies critically—and what that means for DMV drug policy conversations.

Who the mysterious Lizard King might be, how this Psilocybe cubensis strain behaves, why effects vary, and what current psilocybin rules mean for DC, Maryland, and Virginia readers.